Oct 22, 2023
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
Oct 15, 2023
Immutep Announces Publication of Abstracts at ESMO Congress 2023
Oct 02, 2023
Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Sep 20, 2023
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Sep 05, 2023
Immutep to Participate in September Investor Conferences
